FrancophonIA/ELRC3.0 huggingface dataset:
English: Chemical and physical stability of Rixathon diluted in 0.9% sodium chloride solution has been demonstrated for 30 days at 2°C - 8°C and subsequently 24 hours at room temperature (≤25°C).
Croatian: Dokazana je kemijska i fizička stabilnost lijeka Rixathon razrijeđenog u 0,9 %-tnoj otopini natrijeva klorida tijekom 30 dana na temperaturi od 2 °C do 8 °C te potom 24 sati na sobnoj temperaturi (≤ 25°C).
English: Aseptically withdraw the necessary amount of Rixathon, and dilute to a calculated concentration of 1 to 4 mg/mL rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/mL (0.9%) solution for injection or 5% D-Glucose in water.
Croatian: U aseptičkim uvjetima izvucite potrebnu količinu lijeka Rixathon i razrijedite do izračunate koncentracije od 1 do 4 mg/ml rituksimaba u vrećici za infuziju koja sadrži sterilnu apirogenu otopinu natrijevog klorida za injekciju od 9 mg/ml (0,9 %) ili 5 %-tnu vodenu otopinu glukoze.
English: The final analysis confirmed that R-CHOP treatment was associated with a clinically relevant and statistically significant improvement in the duration of event-free survival (the primary efficacy parameter; where events were death, relapse or progression of lymphoma, or institution of a new anti-lymphoma treatment) (p=0.0001).
Croatian: Završna analiza potvrdila je da je liječenje R-CHOPom povezano s klinički relevantnim i statističkim značajnim poboljšanjem trajanja preživljenja bez pojave događaja (primarni parametar djelotvornosti; događajem se smatrala smrt, relaps ili progresija limfoma odnosno početak novog liječenja limfoma) (p = 0,0001).
English: If you are not sure, talk to your doctor, pharmacist or nurse before you are given Rixathon.
Croatian: Ako niste sigurni, obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego što počnete primjenjivati lijek Rixathon.
English: There are no adequate and well-controlled data from studies in pregnant women, however transient B-cell depletion and lymphocytopenia have been reported in some infants born to mothers exposed to rituximab during pregnancy.
Croatian: Ne postoje odgovarajući i dobro kontrolirani podaci iz ispitivanja u trudnica, no u neke dojenčadi čije su majke tijekom trudnoće bile izložene rituksimabu prijavljene su prolazna deplecija B-stanica i limfocitopenija.
English: • Fever or persistent cough
Croatian: • stalnu vrućicu ili kašalj
English: Efficacy in autoantibody (RF and or anti-CCP) seropositive patients Patients seropositive to Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (anti-CCP) who were treated with rituximab in combination with methotrexate showed an enhanced response compared to patients negative to both.
Croatian: Bolesnici seropozitivni na reumatoidni faktor (RF) i/ili antitijela na cikličke citrulinirane peptide (antiCCP) koji su liječeni rituksimabom u kombinaciji s metotreksatom na liječenje su odgovorili bolje nego bolesnici koji su bili negativni na oba antitijela.
English: Granulomatosis with polyangiitis and microscopic polyangiitis Rixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).
Croatian: Granulomatoza s poliangitisom i mikroskopski poliangitis Rixathon je u kombinaciji s glukokortikoidima indiciran za liječenje odraslih bolesnika s teškom aktivnom granulomatozom s poliangitisom (Wegenerova granulomatoza) (GPA) i mikroskopskim poliangitisom (MPA).
English: • Additional risk minimisation measures For the indications non-Hodgkin´s lymphoma (NHL) and Chronic lymphocytic leukaemia
Croatian: • Dodatne mjere minimizacije rizika Za indikacije ne-Hodgkinove limfome (NHL) i kronične limfocitne leukemije (KLL):
English: Results from three other randomised trials using rituximab in combination with chemotherapy regimen other than CVP (CHOP, MCP, CHVP/Interferon-α) have also demonstrated significant improvements in response rates, time-dependent parameters as well as in overall survival.
Croatian: Rezultati drugih triju randomiziranih ispitivanja u kojima je rituksimab primjenjivan u kombinaciji s kemoterapijskim režimom koji nije bio CVP (CHOP, MCP, CHVP / interferon alfa) također su pokazali značajno poboljšanje stopa odgovora, parametara ovisnih o vremenu te ukupnog preživljenja.
English: Cardiac events were reported as serious adverse events (including atrial fibrillation, myocardial infarction, left ventricular failure, myocardial ischaemia) in 3% of patients treated with rituximab compared to < 1% on observation.
Croatian: Srčani događaji su prijavljeni kao ozbiljne nuspojave (uključujući fibrilaciju atrija, infarkt miokarda, zatajenje lijeve klijetke i ishemiju miokarda) u 3 % bolesnika liječenih rituksimabom u usporedbi s < 1 % bolesnika u opservacijskoj skupini.
English: Cyclophosphamide (n=98)
Croatian: Ciklofosfamid (n = 98)
English: Reactivation of hepatitis B infection has also been very rarely reported in RA patients receiving rituximab (see section 4.4).
Croatian: Reaktivacija infekcije hepatitisom B prijavljena je vrlo rijetko u bolesnika s reumatoidnim artritisom koji primaju rituksimab (vidjeti dio 4.4).
English: Neither age, sex, lymphoma grade, initial diagnosis, presence or absence of bulky disease, normal or high LDH nor presence of extranodal disease had a statistically significant effect (Fisher's exact test) on response to rituximab.
Croatian: početna dijagnoza, prisutnost ili odsutnost proširenosti tumora, normalan ili povišeni LDH i ekstranodalna bolest nisu (prema Fisherovom testu vjerojatnosti) statistički značajno utjecali na odgovor na liječenje rituksimabom.
English: Rituximab maintenance treatment significantly prolonged median PFS in patients responding to CHOP induction therapy (median PFS 37.5 months vs. 11.6 months, p < 0.0001) as well as in those responding to R-CHOP induction (median PFS 51.9 months vs. 22.1 months, p=0.0071).
Croatian: Terapija održavanja rituksimabom značajno je produljila medijan PFS-a u bolesnika koji su odgovorili na uvodnu terapiju CHOP-om (medijan PFS-a 37,5 mjeseci u odnosu na 11,6 mjeseci, p < 0,0001) kao i u onih koji su odgovorili na indukciju R-CHOP-om (medijan PFS-a 51,9 mjeseci u odnosu na 22,1 mjesec, p = 0,0071).
English: Rixathon is for intravenous use.
Croatian: Rixathon je namijenjen za intravensku primjenu.
English: What Rixathon is and what it is used for What Rixathon is
Croatian: Što je Rixathon i za što se koristi Što je Rixathon
English: In patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis, methylprednisolone given intravenously for 1 to 3 days at a dose of 1,000 mg per day is recommended prior to the first infusion of Rixathon (the last dose of methylprednisolone may be given on the same day as the first infusion of Rixathon).
Croatian: U bolesnika s granulomatozom s poliangitisom (Wegenerova granulomatoza) ili mikroskopskim poliangitisom se prije prve infuzije lijeka Rixathon preporučuje intravenska primjena metilprednizolona u dozi od 1000 mg na dan tijekom 1 do 3 dana (posljednja doza metilprednizolona može se dati istoga dana kao i prva infuzija lijeka Rixathon).
English: • bacterial or viral infections, bronchitis
Croatian: • bakterijske ili virusne infekcije, upala bronha (bronhitis)
English: The number of rituximab plus low-dose prednisone patients off prednisone therapy or on minimal therapy (prednisone dose of 10 mg or less per day) compared to standard-dose prednisone patients over the 24-month treatment period shows a steroid-sparing effect of rituximab (Figure 4).
Croatian: Broj bolesnika liječenih rituksimabom i niskom dozom prednizona koji nisu primali prednizon ili su primali minimalnu dozu prednizona (10 mg ili manje na dan) u odnosu na bolesnike koji su primali standardnu dozu prednizona tijekom 24-mjesečnog razdoblja liječenja pokazuje poštedni učinak rituksimaba na primjenu steroida (Slika 4).
English: Event free survival Response rate (CR, nPR, or PR) CR rates n.a. n.a.
Croatian: Stopa odgovora (CR, nPR, ili PR) CR stope n.p. n.p.
English: Rituximab may have a minor influence on the ability to drive and use machines.
Croatian: Rituksimab može malo utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
English: Rituximab is associated with infusion-related reactions, which may be related to release of cytokines and/or other chemical mediators.
Croatian: Rituksimab se povezuje s reakcijama na infuziju, koje mogu biti posljedica otpuštanja citokina i/ili drugih kemijskih medijatora.
English: A total of 117 patients (88 with GPA, 24 with MPA, and 5 with renal-limited ANCA-associated vasculitis) in disease remission were randomized to receive azathioprine (59 patients) or rituximab (58 patients) in a prospective, multi-center, controlled, open-label study.
Croatian: Ukupno 117 bolesnika (88 bolesnika s GPA-om, 24 s MPA-om i 5 s ANCA vaskulitisom ograničenim na bubrege) kod kojih je bolest bila u remisiji bilo je randomizirano za primanje azatioprina (59 bolesnika) ili rituksimaba (58 bolesnika) u prospektivnom, multicentričnom, kontroliranom,
English: • nerve damage in arms and legs, paralysed face
Croatian: • oštećenje živaca u rukama i nogama, paraliza lica • zatajenje srca
English: Following induction of remission with other standard of care immunosuppressants, Rixathon maintenance treatment should be initiated during the 4 week period that follows disease remission.
Croatian: Nakon poticanja remisije primjenom drugih imunosupresiva koji se koriste u standardnom liječenju, terapiju održavanja lijekom Rixathon treba započeti tijekom 4-tjednog razdoblja nakon nastupa remisije bolesti.
English: There was no apparent negative impact of the presence of ADA on safety or efficacy in the maintenance therapy clinical trial.
Croatian: Prisutnost antitijela na lijek nije imala primjetnog negativnog utjecaja na sigurnost ni djelotvornost u kliničkom ispitivanju terapije održavanja.
English: Sodium citrate, polysorbate 80, sodium chloride, sodium hydroxide, hydrochloric acid, water for injections.
Croatian: Natrijev citrat, polisorbat 80, natrijev klorid, natrijev hidroksid, kloridna kiselina, voda za injekcije.
English: Clear, colourless to slightly yellowish liquid.
Croatian: Bistra, bezbojna do blago žućkasta tekućina.
English: 4.06 years
Croatian: 4,06 godina
English: Progression-free survival (PFS)
Croatian: Preživljenje bez progresije (PFS)
English: Your doctor may prescribe Rixathon for the treatment of:
Croatian: Liječnik Vam može propisati lijek Rixathon za liječenje sljedećih bolesti:
English: Rituximab mean clearance and volume of distribution were 0.313 L/day (range, 0.116 - 0.726 L/day) and 4.50 L (range 2.25 - 7.39 L) respectively.
Croatian: Srednja vrijednost klirensa rituksimaba iznosila je 0,313 l/dan (raspon: 0,116 do 0,726 l/dan), a volumena raspodjele 4,50 l (raspon: 2,25 do 7,39 l).
English: Overall response rate* chi-squared test p value odds ratio (95% CI) Complete response (CR/CRu) rate* chi-squared test p value odds ratio (95% CI)
Croatian: Stopa ukupnog odgovora* p-vrijednost iz hi-kvadrat testa omjer izgleda (95 % CI) Stopa potpunog odgovora (CR/CRu)* p-vrijednost iz hi-kvadrat testa omjer izgleda (95 % CI)
English: Using a cox regression analysis, the risk of experiencing progressive disease or death was reduced by 61% with rituximab maintenance treatment when compared to observation (95% CI; 45% - 72%).
Croatian: Coxova regresijska analiza pokazala je da terapija održavanja rituksimabom smanjuje rizik od progresije bolesti i smrti za 61 % u usporedbi s opservacijskom skupinom (95 % CI 45 % - 72 %).
English: • The active ingredient in Rixathon is called rituximab.
Croatian: • Djelatna tvar u lijeku Rixathon zove se rituksimab.
English: Maintenance and relapse infusions were administered no sooner than 16 weeks following the previous infusion.
Croatian: Infuzije za terapiju održavanja i liječenje relapsa primjenjivale su se najranije 16 tjedana nakon prethodne infuzije.
English: 18-months p=0.016
Croatian: 18 mjeseci p = 0,016
English: The most common infusion-related reaction symptoms/Preferred Terms included headaches, chills, high blood pressure, nausea, asthenia and pain.
Croatian: Najčešći simptomi reakcija povezanih s infuzijom / preporučeni pojmovi uključivali su glavobolju, zimicu, visok krvni tlak, mučninu, asteniju i bol.
English: In the maintenance therapy clinical trial, the incidence of all-grade neutropenia was 0% for rituximabtreated patients vs 5% for azathioprine treated patients.
Croatian: U kliničkom ispitivanju terapije održavanja incidencija neutropenije svih stupanja iznosila je 0 % u bolesnika liječenih rituksimabom te 5 % u bolesnika liječenih azatioprinom.
English: Concomitant/sequential use of other DMARDs in rheumatoid arthritis The concomitant use of Rixathon and anti-rheumatic therapies other than those specified under the rheumatoid arthritis indication and posology is not recommended.
Croatian: Istodobna/sekvencijska primjena drugih DMARD-a u liječenju reumatoidnog artritisa Istodobna primjena lijeka Rixathon i antireumatskih lijekova koji nisu navedeni u poglavljima o indikaciji i doziranju za reumatoidni artritis se ne preporučuje.
English: In patients with non-Hodgkin's lymphoma and chronic lymphocytic leukaemia, premedication with glucocorticoids should be considered if Rixathon is not given in combination with glucocorticoid-containing chemotherapy.
Croatian: U bolesnika s ne-Hodgkinovim limfomom i KLL-om potrebno je razmotriti premedikaciju glukokortikoidima ako se Rixathon ne primjenjuje u kombinaciji s kemoterapijom koja sadrži glukokortikoide.
English: The clinical relevance of ADA formation in rituximab-treated PV patients is unclear.
Croatian: Klinički značaj pojave antitijela na lijek u bolesnika s PV-om liječenih rituksimabom nije jasan.
English: Angina pectoris, atrial fibrillation, heart failure, myocardial infarction
Croatian: Srčani poremećaji angina pektoris, fibrilacija atrija, zatajenje srca, infarkt miokarda undulacija atrija
English: The pharmacokinetic (PK) parameters in the anti-TNF inadequate responder population, following the same dosage regimen (2 x 1,000 mg, intravenous, 2 weeks apart), were similar with a mean maximum serum concentration of 369 μg/mL and a mean terminal half-life of 19.2 days.
Croatian: Farmakokinetički parametri u populaciji koja nije zadovoljavajuće odgovorila na liječenje TNFinhibitorom su uz isti režim doziranja (2 x 1000 mg, intravenski, u razmaku od dva tjedna) bili slični, uz prosječnu najvišu koncentraciju u serumu od 369 µg/ml i srednji terminalni poluvijek od 19,2 dana.
English: 4 see also section infusion related reactions below.
Croatian: 4 Vidjeti i dio o reakcijama povezanima s infuzijom u nastavku.
English: After a median observation time of 31 months for patients randomised to the induction phase, R-CHOP significantly improved the outcome of patients with relapsed/refractory follicular lymphoma when compared to CHOP (see Table 8).
Croatian: Nakon medijana vremena promatranja od 31 mjeseca za bolesnike randomizirane u indukcijsku fazu, R-CHOP je u usporedbi s CHOP-om znatno poboljšao ishod bolesti u bolesnika s relapsirajućim/refraktornim folikularnim limfomom (vidjeti Tablicu 6).
English: Patients treated with Rixathon may receive non-live vaccinations.
Croatian: Bolesnici liječeni lijekom Rixathon mogu primiti neživa cjepiva.
English: In the clinical trial on induction of remission, the incidence of malignancy in rituximab treated patients in the granulomatosis with polyangiitis and microscopic polyangiitis clinical study was 2.00 per 100 patient years at the study common closing date (when the final patient had completed the follow-up period).
Croatian: U kliničkom ispitivanju poticanja remisije incidencija zloćudnih bolesti u bolesnika liječenih rituksimabom u kliničkom ispitivanju u indikacijama granulomatoze s poliangitisom i mikroskopskog poliangitisa iznosila je 2,00 na 100 bolesnik-godina na dan završetka ispitivanja (kada je posljednji bolesnik dovršio razdoblje praćenja).
English: • Allergic reactions including wheezing or shortness of breath, swelling of the face and tongue,
Croatian: • alergijske reakcije koje obuhvaćaju piskanje ili nedostatak zraka, natečenost lica i jezika, kolaps
English: Kaplan-Meier estimated progression- free rates at 12 months were 78% in the rituximab maintenance group vs. 57% in the observation group.
Croatian: Prema Kaplan-Meierovoj procjeni, stope bez progresije bolesti nakon 12 mjeseci iznosile su 78 % u skupini koja je primala terapiju održavanja rituksimabom u usporedbi s 57 % u opservacijskoj skupini.
English: You will always be given Rixathon as a drip (intra-venous infusion).
Croatian: Lijek Rixathon ćete uvijek primiti ukapavanjem u venu (intravenskom infuzijom).
English: In the maintenance therapy clinical trial, 30/57 (53%) patients in the rituximab arm experienced infections.
Croatian: U kliničkom ispitivanju terapije održavanja infekcije su zabilježene u 30/57 (53 %) bolesnika liječenih rituksimabom.
English: • At the request of the European Medicines Agency;
Croatian: Ažurirani RMP treba dostaviti: • na zahtjev Europske agencije za lijekove.
English: Patients received 2 x 1,000 mg of rituximab separated by an interval of two weeks; in addition to methotrexate (10 - 25 mg/week).
Croatian: Bolesnici su primali 2 × 1000 mg rituksimaba u razmacima od dva tjedna kao dodatak metotreksatu (10 do 25 mg na tjedan).
English: The majority of patients were ANCApositive at diagnosis or during the course of their disease; had histologically confirmed necrotizing small-vessel vasculitis with a clinical phenotype of GPA/MPA, or renal limited ANCA-associated vasculitis; or both.
Croatian: ANCA-pozitivna pri dijagnozi ili tijekom bolesti te je imala histološki potvrđen nekrotizirajući vaskulitis malih krvnih žila i klinički fenotip GPA/MPA, ANCA vaskulitis ograničen na bubrege ili oboje.
English: Immunoglobulins - IgM), chemical disturbances in the blood caused by break-down of dying cancer cells
Croatian: • kratkotrajno povišenje količine nekih vrsta protutijela u krvi (imunoglobulina - IgM), kemijski poremećaji krvi uzrokovani raspadanjem umirućih stanica raka
English: Table 1 ADRs reported in clinical trials or during postmarketing surveillance in patients with NHL and CLL disease treated with rituximab monotherapy/maintenance or in combination with chemotherapy
Croatian: Tablica 1 Nuspojave prijavljene u kliničkim ispitivanjima ili tijekom praćenja nakon stavljanja lijeka u promet u bolesnika s NHL-om i KLL-om koji su rituksimab primali kao monoterapiju/terapiju održavanja ili u kombinaciji s kemoterapijom
English: IRRs for patients with granulomatosis with polyangiitis, microscopic polyangiitis and pemphigus vulgaris were consistent with to those seen for rheumatoid arthritis patients in clinical trials (see section 4.8).
Croatian: Reakcije povezane s infuzijom u bolesnika s granulomatozom s poliangitisom, mikroskopskim poliangitisom i običnim pemfigusom podudarale su se s onima opaženima u bolesnika s reumatoidnim artritisom u kliničkim ispitivanjima (vidjeti dio 4.8).
English: Observation (N=167)
Croatian: Opservacijska skupina (N = 167)
English: Patients were stratified by baseline disease severity (moderate or severe) and randomised 1:1 to receive either rituximab and low-dose prednisone or standard-dose prednisone.
Croatian: Bolesnici su bili stratificirani prema težini bolesti na početku ispitivanja (umjerena ili teška) te su bili randomizirani u omjeru 1:1 za primanje rituksimaba i niske doze prednizona ili standardne doze prednizona.
English: 48-months p=0.0096
Croatian: 48 mjeseci p = 0,0096
English: Rixathon in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia.
Croatian: Rixathon je u kombinaciji s kemoterapijom indiciran za liječenje bolesnika s prethodno neliječenom i relapsirajućom/refraktornom kroničnom limfocitnom leukemijom.
English: Should non-live vaccinations be required whilst receiving rituximab therapy, these should be completed at least 4 weeks prior to commencing the next course of rituximab.
Croatian: Ako je potrebno cijepljenje neživim cjepivom tijekom primjene rituksimaba, ono se mora dovršiti najmanje 4 tjedna prije početka sljedećeg ciklusa rituksimaba.
English: In rheumatoid arthritis patients, immediate depletion of B cells in the peripheral blood was observed following two infusions of 1,000 mg rituximab separated by a 14 day interval.
Croatian: U oboljelih od reumatoidnog artritisa uočena je trenutna deplecija B-stanica u perifernoj krvi nakon dvije infuzije od 1000 mg rituksimaba u razmaku od 14 dana.
English: Prednisone tapering was to be completed by 6 months from the start of trial treatment.
Croatian: Postupno smanjivanje doze prednizona moralo se dovršiti do isteka 6 mjeseci od prve primjene ispitivanog lijeka.
English: In a further clinical study, a total of 57 severe, active GPA and MPA patients in disease remission were treated with rituximab for the maintenance of remission (see section 5.1).
Croatian: U dodatnom je kliničkom ispitivanju ukupno 57 bolesnika s teškim aktivnim GPA-om i MPA-om kod kojih je bolest bila u remisiji primalo rituksimab za održavanje remisije (vidjeti dio 5.1).
English: • Infections such as bronchial tube inflammation (bronchitis)
Croatian: • infekcije kao što je upala bronha (bronhitis)
English: Therefore, in patients with a known cardiac history, and those who experienced prior cardiopulmonary adverse reactions, the risk of cardiovascular complications resulting from infusion reactions should be considered before treatment with Rixathon and patients closely monitored during administration.
Croatian: Stoga se u bolesnika s anamnezom srčanih poremećaja i onih koji su ranije imali nuspojave na srcu i plućima prije liječenja lijekom Rixathon, mora razmotriti rizik od razvoja kardiovaskularnih komplikacija kao posljedice reakcije na infuziju te ih se mora pažljivo nadzirati tijekom liječenja.
English: In the induction of remission clinical trial, at 6 months, in the rituximab group, 27%, 58% and 51% of patients with normal immunoglobulin levels at baseline, had low IgA, IgG and IgM levels, respectively compared to 25%, 50% and 46% in the cyclophosphamide group.
Croatian: U kliničkom ispitivanju poticanja remisije su nakon 6 mjeseci u skupini koja je primala rituksimab vrijednosti IgA, IgG i IgM bile snižene u 27 %, 58 % odnosno 51 % bolesnika koji su na početku ispitivanja imali normalne vrijednosti imunoglobulina, u usporedbi s 25 %, 50 % odnosno 46 % bolesnika u skupini koja je primala ciklofosfamid.
English: For CLL patients whose lymphocyte counts are > 25 x 109/L it is recommended to administer prednisone/prednisolone 100 mg intravenous shortly before infusion with Rixathon to decrease the rate and severity of acute infusion reactions and/or cytokine release syndrome.
Croatian: U bolesnika s KLL-om koji imaju broj limfocita > 25 x 109/l preporučuje se primjena prednizona/prednizolona u dozi od 100 mg intravenski neposredno prije infuzije lijeka Rixathon kako bi se smanjila stopa i težina akutne infuzijske reakcije i/ili sindroma otpuštanja citokina
English: Rixathon should not be administered to patients with an active, severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see section 4.3) or severely immunocompromised patients (e.g. where levels of CD4 or CD8 are very low).
Croatian: Rixathon se ne smije primijeniti bolesnicima s aktivnom teškom infekcijom (npr. tuberkulozom, sepsom i oportunističkim infekcijama, vidjeti dio 4.3) ili teško imunokompromitiranim bolesnicima (npr. kada su razine CD4 ili
English: 2 vials of 10 mL 3 vials of 10 mL
Croatian: 2 bočice od 10 ml 3 bočice od 10 ml
English: Progression of Kaposi's sarcoma has been observed in rituximab-exposed patients with pre-existing Kaposi's sarcoma.
Croatian: Progresija Kaposijeva sarkoma primijećena je u bolesnika izloženih rituksimabu koji su imali Kaposijev sarkom prije početka liječenja.